Volume 149, Issue 3, Pages 649-659 (September 2015) Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease  Michael Charlton, Gregory T. Everson, Steven L. Flamm, Princy Kumar, Charles Landis, Robert S. Brown, Michael W. Fried, Norah A. Terrault, Jacqueline G. O'Leary, Hugo E. Vargas, Alexander Kuo, Eugene Schiff, Mark S. Sulkowski, Richard Gilroy, Kymberly D. Watt, Kimberly Brown, Paul Kwo, Surakit Pungpapong, Kevin M. Korenblat, Andrew J. Muir, Lewis Teperman, Robert J. Fontana, Jill Denning, Sarah Arterburn, Hadas Dvory-Sobol, Theo Brandt-Sarif, Phillip S. Pang, John G. McHutchison, K. Rajender Reddy, Nezam Afdhal Princy Kumar, Eugene Schiff, Nezam Afdhal, Robert S. Brown, Michael Fried, Kris Kowdley, Norah Terrault, Michael Charlton, Paul Kwo, Steve Flamm, John Lake, Greg Everson, Mark Sulkowski, Michael Curry, Rajender Reddy, Lewis Teperman, Hugo Vargas, Surakit Pungpapong, Andrew Muir, Atif Zaman, Kimberly Brown, Charles Landis, Alexander Kuo, Robert Fontana, Jacqueline O'Leary, Richard Gilroy, Obaid Shaikh, Kevin Korenblat, Richard Stravitz, Kymberly Watt, Narayanan Menon, James Bredfeldt, Carlos Romero-Marrero Michael Charlton, Gregory T. Everson, Steven L. Flamm, Princy Kumar, Charles Landis, Robert S. Brown, Michael W. Fried, Norah A. Terrault, Jacqueline G. O'Leary, Hugo E. Vargas, Alexander Kuo, Eugene Schiff, Mark S. Sulkowski, Richard Gilroy, Kymberly D. Watt, Kimberly Brown, Paul Kwo, Surakit Pungpapong, Kevin M. Korenblat, Andrew J. Muir, Lewis Teperman, Robert J. Fontana, Jill Denning, Sarah Arterburn, Hadas Dvory-Sobol, Theo Brandt-Sarif, Phillip S. Pang, John G. McHutchison, K. Rajender Reddy, Nezam Afdhal Princy Kumar, Eugene Schiff, Nezam Afdhal, Robert S. Brown, Michael Fried, Kris Kowdley, Norah Terrault, Michael Charlton, Paul Kwo, Steve Flamm, John Lake, Greg Everson, Mark Sulkowski, Michael Curry, Rajender Reddy, Lewis Teperman, Hugo Vargas, Surakit Pungpapong, Andrew Muir, Atif Zaman, Kimberly Brown, Charles Landis, Alexander Kuo, Robert Fontana, Jacqueline O'Leary, Richard Gilroy, Obaid Shaikh, Kevin Korenblat, Richard Stravitz, Kymberly Watt, Narayanan Menon, James Bredfeldt, Carlos Romero-Marrero  Gastroenterology  Volume 149, Issue 3, Pages 649-659 (September 2015) DOI: 10.1053/j.gastro.2015.05.010 Copyright © 2015 AGA Institute Terms and Conditions

Figure 1 Patient disposition during the study. AE, adverse event; LDV, ledipasvir; SOF, sofosbuvir; LT, liver transplantation; RBV, ribavirin. Gastroenterology 2015 149, 649-659DOI: (10.1053/j.gastro.2015.05.010) Copyright © 2015 AGA Institute Terms and Conditions

Figure 2 Change from baseline to post-treatment week 4 in MELD scores in patients with Child–Pugh B and C disease. The figure shows the change from baseline in MELD scores in patients in groups 1, 2, 5, and 6. MELD is a scoring system for assessing the severity of chronic liver disease and was designed to measure the urgency of the need for liver transplantation. The scores were calculated using the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time. The resulting scores range from 6 (the least ill patients) to 40+ (gravely ill patients). The 3-month mortality rate was 71% for patients with a score of 40 or higher, 53% for patients with a score of 30–39, 20% for patients with a score of 20–29, 6% for patients with a score of 10–19, and 2% for patients with a score of 9 or less.26 Each black bar represents an individual patient. Missing patient data for the post-treatment week 4 visit are indicated in the figure. Gastroenterology 2015 149, 649-659DOI: (10.1053/j.gastro.2015.05.010) Copyright © 2015 AGA Institute Terms and Conditions